Aurinia Pharmaceuticals Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Aurinia Pharmaceuticals Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Aurinia Pharmaceuticals Inc. do? Business model and key facts
Get the full picture of Aurinia Pharmaceuticals Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 128
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Stocks related to Aurinia Pharmaceuticals Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Aurinia Pharmaceuticals Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Aurinia Pharmaceuticals Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
